|

Post-Marketing Clinical Study of High-Pressure Cutting Balloon

RECRUITINGN/ASponsored by BrosMed Medical Co., Ltd
Actively Recruiting
PhaseN/A
SponsorBrosMed Medical Co., Ltd
Started2026-09
Est. completion2028-12
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

This study is designed as a prospective, multicenter, 1:1 randomized controlled trial. It plans to enroll 280 patients with moderate-to-severe calcified coronary lesions who are candidates for IVUS-guided DES implantation. Subjects will be randomized in a 1:1 ratio to the experimental group (n=140) or the control group (n=140). The primary endpoint is the MSA measured by IVUS immediately after the procedure, with the purpose of verifying the safety and efficacy of the high-pressure cutting balloon in optimizing stent implantation outcomes.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥18 years;
* Patients with coronary artery disease who indicate IVUS-guided drug-eluting stent implantation;
* Moderate-to-severe calcified lesions on coronary angiography;
* Target lesion is a de novo lesion in a native vessel that has not received any prior interventional treatment;
* Target vessel diameter of 2.5-4.0 mm, with guidewire crossing of the target lesion;
* In patients with multiple lesions, only one lesion will be selected as the target lesion in this study. If target and non-target lesions are treated during the same procedure, the target and non-target lesions must be located in different vessel branches; furthermore, the non-target lesion must be treated first, and the target lesion may be treated only after successful revascularization of the non-target lesion without severe angiographic complications;
* Provision of written informed consent.

Exclusion Criteria:

* Life expectancy \<1 year;
* Cardiogenic shock or hemodynamic instability;
* Left main coronary artery disease;
* Chronic total occlusion;
* Bifurcation lesions planned for a "two-stent strategy";
* Active bleeding;
* Known history of allergy to contrast media or metals;
* Patients with a bleeding tendency, contraindications to antiplatelet or anticoagulant therapy, or inability to receive anticoagulation therapy;
* New-onset stroke/transient ischemic attack within 6 months;
* Pregnant or lactating women;
* Left ventricular ejection fraction \<25%, or NYHA functional class IV, or Killip class ≥2;
* Non-target vessel revascularization within 30 days before randomization with complications.

Conditions3

CalcificationCoronary Artery DiseaseHeart Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.